FMXIN002 double dose + FMXIN002 double dose + NAC + FMXIN002 single dose + FMXIN002 single dose + NAC + Epinephrine for anaphylaxis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Nov 2025: Trial started, NCT07228325
  2. 14 Nov 2025: Trial registered, NCT07228325

The trials

NCT07228325: Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis

State
Under way
Phase
Phase 1 and Phase 2
People
50 planned
Started
3 Nov 2025
Primary completion
Mar 2026
Arms
FMXIN002 Repeated doses in the same nostril, FMXIN002 Repeated doses in the opposite nostril
Results
None posted
  1. 3 Nov 2025: Trial started
  2. 14 Nov 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.